Disease Analysis: Asthma

13 New Drugs Pass Muster At The EMA

• Hikma Launches Long-Awaited US Advair Rival
• Teva Seeks To Simplify With Canadian Inhalers
• Teva Completes ‘Digihaler Family’
• Perrigo’s Albuterol Advantage Blunted By Recall
• GSK’s Trelegy Ellipta Is First Triple Combination Approved For Asthma In the US
• US Albuterol Market Hots Up With Lupin ProAir Approval
• Aurobindo’s US Respiratory Filing Could Rival Teva’s Qvar
• Genentech Seeks Self-Administration Option For Xolair
• Teva Launches ProAir Dry Powder Digital Inhaler
• Novartis Triple Combo Enerzair Gets EU OK For Asthma
• Japan Nods For Enerzair And Atectura For Asthma
• Cipla Files ANDA For Advair Rival
• Mylan Launches Advair Rival In Canada
• England’s NICE Says No To Sanofi’s Dupixent For Asthma
• US FDA Orders Singulair Boxed Warning On Neuropsychiatric Events Despite ‘Limited’ Evidence

Figure 1: Trends in prevalent cases of asthma, 2018–27
Figure 2: Overview of pipeline drugs for asthma in the US
Figure 3: Pipeline drugs for asthma, by company
Figure 4: Pipeline drugs for asthma, by drug type
Figure 5: Pipeline drugs for asthma, by classification
Figure 6: Probability of success in the asthma pipeline
Figure 7: Clinical trials in asthma
Figure 8: Top 10 drugs for clinical trials in asthma
Figure 9: Top 10 companies for clinical trials in asthma
Figure 10: Trial locations in asthma
Figure 11: Asthma trials status
Figure 12: Asthma trials sponsors, by phase
Figure 13: The publisher’s drug assessment summary for asthma
Figure 14: Market dynamics in asthma
Figure 15: Future trends in asthma
Figure 16: Tezepelumab for Asthma (December 22, 2020): Phase III - SOURCE
Figure 17: Tezepelumab for Asthma (November 10, 2020): Phase III - NAVIGATOR
Figure 18: GB001 for Asthma (October 13, 2020): Phase IIb - LEDA
Figure 19: QAW039 for Asthma (December 16, 2019): Phase III - LUSTER 1, Phase III - LUSTER 2
Figure 20: Seliforant for Asthma (December 2, 2019): Related Drug - Trial Data
Figure 21: Masitinib for Asthma (November 7, 2019): Phase III - AB07015
Figure 22: QAW039 for Asthma (October 22, 2019): Phase III - ZEAL-1, Phase III - ZEAL-2
Figure 23: Atectura Breezhaler for Asthma (September 30, 2019): Phase III - PALLADIUM
Figure 24: Enerzair Breezhaler for Asthma (September 30, 2019): Phase III - IRIDIUM (w/QMF149)
Figure 25: Trimbow for Asthma (September 30, 2019): Phase III - TRIGGER, Phase III - TRIMARAN
Figure 26: Key upcoming events in asthma

Table 1: Patient severity in asthma
Table 2: GINA treatment recommendations for asthma
Table 3: NAEPP EPR-3 Guidelines and Focused Update
Table 4: Prevalent cases of asthma, 2018–27
Table 5: Marketed drugs for asthma
Table 6: Pipeline drugs for asthma in the US
Table 7: Historical global sales, by drug ($m), 2015–19
Table 8: Forecasted global sales, by drug ($m), 2021–25
Table 9: Tezepelumab for Asthma (December 22, 2020)
Table 10: Tezepelumab for Asthma (November 10, 2020)
Table 11: TD-8236 for Asthma (November 5, 2020)
Table 12: GB001 for Asthma (October 13, 2020)
Table 13: QAW039 for Asthma (December 16, 2019)
Table 14: Seliforant for Asthma (December 2, 2019)
Table 15: Masitinib for Asthma (November 7, 2019)
Table 16: QAW039 for Asthma (October 22, 2019)
Table 17: Atectura Breezhaler for Asthma (September 30, 2019)
Table 18: Enerzair Breezhaler for Asthma (September 30, 2019)
Table 19: Trimbow for Asthma (September 30, 2019)